Patent Application: Composition for Mitigating Veisalgia and Nausea

The USPTO has published a patent application (US20260083695A1) for a composition designed to reduce veisalgia (hangover) symptoms and nausea. The application details an orally deliverable formulation containing dihydromyricetin, acetylcysteine, and specific antiemetics, with a filing date of September 10, 2025.

Gamma-hydroxybutyrate Formulations with Improved Pharmacokinetics

The USPTO has published a new patent application, US20260083696A1, detailing modified release formulations of gamma-hydroxybutyrate with improved dissolution and pharmacokinetic properties. The application was filed on October 1, 2025, by inventors Jordan Dubow, Claire Megret, Hervé Guillard, and Jean-François Dubuisson.

Patent Application: Composition for Controlling Aquatic Organism Infections

The USPTO has published a new patent application (US20260083697A1) from B. G. Negev Technologies and Applications Ltd. The application details a composition containing an esterified fatty acid for preventing or treating monogenean infections in aquatic organisms.

Patent Application: Synergistic Stimulation for Cystic Fibrosis Mucus Obstruction

The USPTO has published a new patent application (US20260083698A1) detailing methods for treating mucus obstruction in cystic fibrosis and other disorders. The application, filed on September 19, 2023, describes a combination therapy involving a b-adrenergic agonist or adenylate cyclase activator with a cholinergic agonist.

Patent Application for Psychoactive Medicines Treating Disorders

The USPTO has published patent application US20260083699A1 by Transcend Therapeutics, Inc. The application details psychoactive medicines, including 2C-B and cathinones, for treating psychiatric and neurological conditions. The filing date was December 4, 2025.

Patent Application: Methods Treat/Prevent Protein Aggregation Diseases Using Sulfatase Inhibitor

The USPTO has published a new patent application (US20260083700A1) detailing methods for treating and/or preventing protein-aggregation diseases by administering a sulfatase inhibitor. The application was filed on September 26, 2025, by inventors Manuel J. Muñoz, Ángel M. Carrión, and Mercedes M. Pérez-Jiménez.

Patent Application for Inflammatory Condition Treatment Compositions

The USPTO has published a new patent application (US20260083701A1) for compositions and methods related to the treatment of inflammatory conditions. The application details compounds and formulations aimed at managing inflammation and associated symptoms like dryness, itching, and redness.

Patent Application: Inhalation Formulation for Treating IPF Disease

The USPTO has published a patent application (US20260083702A1) detailing an inhalation formulation for treating Idiopathic Pulmonary Fibrosis (IPF) disease. The application describes formulations using specific drugs like apremilast and roflumilast, aiming to improve bioavailability and clinical efficacy compared to oral administration.

USPTO Patent Application for Indoline Derivatives as Serotonergic Agents

The USPTO has published a patent application (US20260083703A1) for indoline derivatives intended for use as serotonergic agents. The application details potential treatments for disorders related to serotonin receptor activation, including psychosis, mental illnesses, and CNS disorders.

USMCA Labor Mechanism Dispute Settlement Roster Applications Invited

The Office of the United States Trade Representative (USTR) is inviting applications from eligible individuals to serve on specialized labor dispute settlement panels under the USMCA. Applications must be received by April 27, 2026, and are to be submitted through Regulations.gov.